36 results about "Tropism" patented technology

The present disclosure relates to novel adeno-associated adenovirus (AAV) vectors comprising targeting peptides. More particularly, the present disclosure relates to an adeno-associated serotype 2 virus vector, AAV2, comprising a transgene encoding LIGHT wherein the viral capsid of the AAV2 vector comprises a targeting peptide that alters its tropism to target tumor endothelial cells; and a use of the carrier. The disclosure also relates to the use of said vectors in therapy, in particular in the treatment of cancer.

The invention discloses a bipeptide modified bionic nano-vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The dipeptide modified bionic nano-vesicle comprises nano-particles formed by PLGA (poly (lactic-co-glycolic acid)), and the nano-particles are loaded with a medicine with a nerve protection or nerve repair effect; the surface of the nanoparticle is coated with a macrophage membrane for expressing RVG peptide and T7 peptide. The bipeptide modified bionic nano-vesicle simultaneously presents T7 peptide and RVG peptide through an engineered macrophage membrane, the T7 peptide is combined with a blood-brain barrier transferrin receptor through high affinity to realize efficient brain entry, astrocytes in the brain are specifically recognized by virtue of the RVG peptide, accurate recognition and delivery of target cells in a focus area are realized, and the bipeptide modified bionic nano-vesicle has a good application prospect. Meanwhile, the natural inflammation tropism and immune escape ability of a macrophage membrane are reserved, and the problems that a traditional drug delivery system is low in targeting precision, and cross-barrier distribution and intracerebral distribution are difficult to cooperate are solved.

The disclosure relates to compositions, methods, and processes for the preparation, use, and / or formulation of adeno-associated virus capsid proteins, wherein the capsid proteins comprise targeting peptide inserts for enhanced tropism to a target tissue.

The technology described herein provides variant adeno-associated viral capsid polypeptides and viruses comprising the same. Further provided herein are methods for delivering a viral payload using viruses comprising variant capsid polypeptides described herein. Described herein are viral vectors comprising a variant sequence of the capsid gene, VP1. In particular, viral vectors with capsid polypeptide mutations that modify tropism of the viral particles relative to particles with wild-type capsid polypeptide are described.

The invention discloses a phagostimulant capable of improving the prevention and control effect of cotton flower thrips and application of the phagostimulant. The phagostimulant is prepared from the following components in parts by weight: 10 to 30 parts of p-methoxycinnamyl aldehyde, 5 to 40 parts of anisaldehyde, 40 to 70 parts of ethyl nicotinate and 10 parts of a cosolvent. The phagostimulant is prepared from the following components in parts by weight: 10 to 30 parts of p-methoxycinnamyl aldehyde, 5 to 40 parts of anisaldehyde, 40 to 70 parts of ethyl nicotinate and 10 parts of cosolvent. By utilizing the tropism of the cotton flower thrips to specific volatile compounds and through the synergistic effect of the three plant source compounds, pests hidden in stamens, petal wrinkles, leaf backs and other hidden parts are attracted to a pesticide application area, the contact area of insect bodies and the pesticide is remarkably increased, and therefore the prevention and control effect is improved. Field tests show that when an optimal formula (the ratio of p-methoxycinnamaldehyde to anisaldehyde to ethyl nicotinate to the cosolvent is 20: 20: 50: 10) is matched with spinetoram for use, the control effect can reach 84.43%-92.22%, the control effect is remarkably improved compared with that of single use of an insecticide, and a good control effect is shown. The method is safe and environment-friendly, reduces the amount and increases the efficiency, and has remarkable economic and ecological benefits.

This invention relates to a self-adjuvanted biomimetic lipid nanoparticle, its microfluidic assembly method, and its anti-tumor applications. The self-adjuvanted biomimetic lipid nanoparticle has a structure in which an activated dendritic cell membrane (ADCM) is coated on the surface of a lipid nanoparticle (LNP) loaded with mRNA. The advancements of this invention compared to traditional LNPs are: the self-adjuvanted biomimetic lipid nanoparticle (ADCM-LNP) exhibits a faster cellular uptake rate and higher transfection efficiency, thereby inducing a strong Th1-type immune response and a potent CTL-mediated tumor-killing effect. In vivo biodistribution studies have shown that this system exhibits significant spleen-targeting (splenic tropism) and demonstrates excellent therapeutic efficacy in a HER2-positive breast cancer model.

The application discloses a method for constructing a space-layered composite particle by salt-tropism induction and application thereof, and comprises the following steps: inoculating functional bacteria into an anaerobic ammonia oxidation granular sludge system, so that the functional bacteria and the anaerobic ammonia oxidation granular sludge form a mixed system; the functional bacteria are heterotrophic bacteria with salt-tolerant characteristics Bacillus pumilus NJUST51 strain; the mixed system is operated under anaerobic conditions, and salt is gradually added into influent, so that the salinity is increased to 0.5% to 1.0%; under the action of salt selection pressure, the functional bacteria are enriched on the surface of the granules to form a space-layered structure, so that a composite granule system is constructed. The application realizes stable construction by salt-tropism induction, improves the salt resistance and toxicant resistance stability of the anaerobic ammonia oxidation system, and expands the application range of the system in treatment of high-salinity and organic-toxicity industrial wastewater.

The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV capsid protein and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.

Provided are an adeno-associated virus mutant and the use thereof. The amino acid sequence of the adeno-associated virus capsid protein mutant comprises a sequence shown as any one of SEQ ID Nos. 1-6. Further provided is the use of the adeno-associated virus capsid protein mutant and an expression vector, host cell and recombinant adeno-associated virus thereof in the preparation of a drug delivery tool for preventing and / or treating muscle or cardiac diseases. The provided adeno-associated virus capsid protein mutant has muscle or heart targeting ability, the muscle targeting ability is increased by a maximum of about 496.41 times, the liver and spleen tropism is nearly 100 times lower than that of a control group, and said mutant has good specificity, and exhibits good effect in NHPs.

Disclosed are an rBJ-VVL plasmid, a mutant strain of NADC34-like PRRSV-2 and a preparation method therefor and application thereof. Further disclosed is an NADC34-like PRRSV-2-specific vaccine. In the present disclosure, a modified strain rBJ-VVL with tropism for Marc-145 cells is obtained by precisely mutating an amino acid at positions 91 / 97 / 98 of GP2a; the modified virus constructed in the present disclosure can be propagated in Marc-145 cells, cause cytopathic effects and form plaques when inoculated into Marc-145 cells for serial passage; the resulting Marc-145 cell-passaged viruses have an extremely viral load, and a large number of new progeny viruses can be obtained in a short time; and the Marc-145-adapative modified strain cultured in the present disclosure is used to create a first NADC34-like PRRSV-2-specific vaccine.

The disclosure relates to compositions, methods, and processes for the preparation, use, and / or formulation of adeno-associated virus capsid proteins, wherein the capsid proteins comprise targeting peptide inserts for enhanced tropism to a target tissue.

The present disclosure provides a modified AAV capsid protein comprising a targeting peptide in variable region VIII (VR, VIII) and / or a peptide segment in variable region I (VR I). The modified AAV capsid protein can form an rAAV, which has a preferred tropism, specificity or biodistribution in vivo or in vitro. The rAAV of the present disclosure can be used for gene therapies targeted at a specific tissue.

The present disclosure provides a modified AAV capsid protein comprising a targeting peptide in a variable region VIII (VRVIII). The modified AAV capsid protein may form an rAAV having a preferred tropism, specificity, or biological distribution in vivo or in vitro. The rAAVs of the present disclosure can be used in gene therapy targeting specific tissues.

The application discloses a porcine reproductive and respiratory syndrome mutant virus and a construction method and application thereof. The application accurately analyzes key amino acid sites of PRRSV-1 determining Marc-145 cell tropism, specifically, 88(F), 94(I) and 95(L) amino acids of GP2a, 70(G), 72(N), 80(D), 154(I), 158(H) and 163(L) amino acids of GP3, and 49(D), 53(L), 54(R) and 57(G) amino acids of GP4. Three Marc-145 cell non-adapted strains are precisely point mutated, three PRRSV-1 modified strains which can adapt to Marc 145 cell in vitro passage culture are obtained, the strains can be stably passed in vitro and have good replication efficiency, and Marc-145 cells infected by the strains can produce obvious cytopathic effect, and the strains are expected to be used as a new type of PRRSV-1 vaccine.

Recombinant adeno-associated virus (AAV) vectors are a major gene delivery platform, and the clinical use of several AAV-mediated therapies has recently been approved. Disclosed herein are compositions comprising AAV capsid proteins exhibiting improved tropism and improved transduction efficiency to renal cells and kidney-associated cells, as well as methods for using AAV particles and AAV vectors containing these AAV capsid proteins to efficiently deliver a gene or transgene of interest to target cells or tissues, and to treat subjects requiring treatment.

The present disclosure generally relates to engineered viral capsid polypeptides with enhanced tropism to certain target tissues and uses thereof. Also disclosed are polynucleotides encoding the engineered viral capsid polypeptides, and vectors, cells, or compositions comprising the same and uses thereof.

The invention discloses a kit for efficiently capturing fungal pathogen nucleic acid from soil as well as a preparation method and application of the kit. The preparation method comprises the following steps: the kit comprises a solid culture medium enrichment bar, a rapid lysis solution and a neutralization solution. After the enrichment bar is inserted into the soil to be detected, the pathogenic bacteria are enriched on the culture medium matrix of the enrichment bar by utilizing the isotropic growth of the pathogenic bacteria, and the target pathogenic bacteria are physically purified from the soil environment rich in inhibitors. According to the method, nucleic acid purification is not needed, rapid alkali lysis can be directly carried out on the enriched product, and the obtained nucleic acid lysis solution can be directly used as a detection template for high-sensitivity molecular detection. According to the method, the problem of interference of the soil inhibitor on molecular detection is fundamentally solved, high-difficulty soil nucleic acid extraction is simplified into high-efficiency rapid nucleic acid extraction, and a key solution is provided for field on-site detection.

The disclosure relates to compositions, methods, and processes for the preparation, use, and / or formulation of adeno-associated virus capsid proteins, wherein the capsid proteins comprise targeting peptide inserts tor enhanced tropism to a target tissue.

The invention relates to a type II herpes simplex virus strain HSV-2 / KM-1 and application thereof, and belongs to the technical field of virus microorganisms. The II-type herpes simplex virus strain HSV-2 / KM-1 is preserved in the China Center for Type Culture Collection on July 25, 2025, and the preservation number of the II-type herpes simplex virus strain HSV-2 / KM-1 is CCTCC (China Center for Type Culture Collection) NO: V202550. The II-type herpes simplex virus strain HSV-2 / KM-1 disclosed by the invention has cell tropism and tends to infect genital epithelial cells; the II-type herpes simplex virus strain HSV-2 / KM-1 is applied to neutralizing antibody detection of mouse serum, and the instrumental effect of the II-type herpes simplex virus strain HSV-2 / KM-1 in immunogenicity evaluation of vaccines is disclosed. According to the invention, the II-type herpes simplex virus strain HSV-2 / KM-1 is simultaneously utilized to successfully construct a Hartley guinea pig genital herpes model or a BALB / c mouse genital herpes model, and the models can be used as new tools for HSV-2 vaccine evaluation.

Described herein are engineered and chimeric VP capsid polypeptides with enhanced tropism for target tissues (e.g., CNS or eye tissues) and enhanced functional transduction. The engineered VP capsid polypeptides are capable of assembling into recombinant AAV (rAAV) capsids for delivery of payload sequences to target tissues (e.g., CNS or eye tissues). Also described herein are methods of using rAAV capsids assembled from the engineered VP capsid polypeptides to deliver and express a payload, such as a guide RNA, in target tissues (e.g., CNS or eye tissues).

The present disclosure provides a modified AAV capsid protein comprising a targeting peptide in variable region VIII (VR VIII) and / or a peptide segment in variable region I (VR 1). The modified AAV capsid protein can form a rAAV that has a preferred tropism, specificity, or biodistribution in vivo or in vitro. The rAAV of the present disclosure can be used for gene therapy targeted at a particular tissue.

Provided are modified cells and cell lines containing extracellular enveloped viruses (EEV), methods of producing serum-resistant EEVs, and programmed EEVs for systemic oncolytic viral therapy. The viruses are high EEV producing viruses that contain genome modifications that alter properties and / or activities of the viruses. The cells and cell lines are modified to encode polypeptides or peptides that are displayed on their membranes, which, when virus is propagated in the cells, encases the virus so that the polypeptides and peptides from the cell membrane are displayed on the virus. The viruses, thus contain modified outer envelopes that display polypeptides and / or peptides encoded by the virus and from the cell membranes. This combination provides viruses whose properties and activities can be programmed by virtue of the cells in which they are produced and viral genome modifications. The viruses can be used for treating cancers or, because the properties of the virus, including tropisms, other diseases, disorders, and conditions involving targeted cells.

Provided are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with tropisms showing increased specificity and efficiency of viral transduction in targeted cell-types, for e.g., the brain and the liver. Therapeutic and biomedical research applications of the rAAVs are also described, including without limitation methods of discovering rAAVs using a multiplexed Cre recombination-based AAV targeted evolution (M-CREATE) method, and methods of treating various diseases and conditions by rAAV-mediated transgene therapy.

The application discloses a kind of plant auxin immunolocalization method and application, belong to immunolocalization technical field.The method includes the following steps: step 1, preparation of root section;2, material fixation;Step 3, permeation;Step 4, blocking;Step 5, antibody incubation;Step 6, staining and observation.The application also provides the application of the plant auxin immunolocalization method in plant tropism growth process.The application is based on the existing immunolocalization technology for further optimization, and the auxin of larger volume root system is finely positioned in layers, so as to study the distribution change of auxin under growth and development or adversity conditions.

The invention relates to the technical field of agricultural microorganisms, and discloses a corn rhizosphere microbial complex microbial inoculant for regulating and controlling the taxis of spodoptera frugiperda, which comprises the following components in percentage by mass: 15-35% of fermentation carbon source mixed liquor, 5-25% of complex microbial fermentation product, and 50-80% of carrier and auxiliary material component, wherein the fermentation carbon source mixed solution is composed of molasses accounting for 18-28% of the total mass of the fermentation carbon source mixed solution, crude glycerin accounting for 8-22% of the total mass of the fermentation carbon source mixed solution, cellulase hydrolysate accounting for 38-48% of the total mass of the fermentation carbon source mixed solution, corn starch processing byproduct liquid accounting for 10-15% of the total mass of the fermentation carbon source mixed solution, and the balance deionized water; multiple types of carbon sources are provided through fermentation carbon source mixed liquid, the compound microbial fermentation product is subjected to two-stage culture mixing and then is used for parallel fermentation, and a carrier and auxiliary material components are used for fixing and forming, so that the compound microbial fermentation product keeps stable coexistence and metabolism synergy in the preparation and use processes; therefore, the pest behavior resistance evolution capability is enhanced in the application.

The invention relates to the technical field of agricultural biology, in particular to dsRNA of a pinus massoniana gene11 gene and application of the dsRNA, and the dsRNA is composed of a sense RNA chain shown in SEQ ID NO: 1 and an antisense RNA chain reversely complementary with the sense RNA chain. According to the dsRNA of the pine caterpillars gene11 gene and the preparation method and application thereof, the dsRNA is injected into pine caterpillars, target genes of the pine caterpillars are efficiently silenced, the death rate of the pine caterpillars can be increased, feeding behavior taxis is reduced, food digestion is affected, and finally the prevention and treatment effect is achieved; and a new effective way is provided for preventing and treating the pine caterpillars.

The present disclosure provides a modified AAV capsid protein comprising a targeting peptide in variable region VIII (VR VIII). The modified AAV capsid protein can form an rAAV, which has a preferred tropism, specificity or biodistribution in vivo or in vitro. The rAAV of the present disclosure can be used for gene therapies targeted at a specific tissue.

The present invention relates to recombinant adeno-associated viruses (rAAVs) having either wild-type capsid proteins or capsid proteins engineered to be atropic or have limited tropism which may be further engineered by insertion of a DARPin targeting element that confers and / or enhances desired properties, particularly increased transduction in CNS or muscle cells or other target tissue relative to a rAAV having a reference capsid.

The present invention relates to novel neurotropic adeno-associated virus (AAV) capsid variants. In particular, the present invention relates to novel AAV capsid variants that are effective to transduce cells in the CNS after systemic administration, but show reduced transduction of the peripheral organ. The present invention further relates to methods for identifying AAV capsid variants having one or more desired characteristics such as, for example, a combination of CNS tropism and peripheral organ de-targeting.